BPaLM: Overview
- Burden of DR-TB in India
- Types of Drug Resistance Tuberculosis -DRTB
- History of Programmatic Management of Drug Resistant TB [PMDT] in India
- Newer Anti-TB Drugs
- Newer Anti-TB Drugs: Pretomanid [Pa]
- WHO recommendation for newer, shorter, oral regimens
- BPaLM regimen for DR-TB
- Evidence for the efficacy of BPaL regimen in DR-TB
- Rationale for continuation of Moxifloxacin in BPaLM regimen irrespective of FQ resistance
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen
- 2024 NTEG Recommendations for DR-TB Management
- 2024 Updates in DR-TB Management
BPaLM: Updates in Management of Dr-TB
- Integrated DR-TB Algorithm
- Eligibility Criteria for BPaLM
- Relative contraindications Criteria for BPaLM
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria
- Pre-treatment Evaluation [PTE] of DR-TB Patients​
- TB Disease Severity considerations for Management
- Treatment initiation for MDR/RR-TB cases
- Overview of Treatment Course for patients on BPaLM regimen
- Management of BPaLM ineligible patients
- Regimen modification for patients on BPaLM regimen
- Implementation Consideration for BPaLM regimen
- Extension criterion for BPaLM regimen
- Screening of patients on BPaLM regimen for Linezolid toxicity
- Follow-up monitoring of BPaLM
- Follow-up monitoring of modified shorter oral MDR/RR-TB regimen with Lzd
- Regimen Modification of Shorter Oral MDR/RR regimen containing Bdq and Lnz
- Principles of Switching from BpalL/ Shorter Oral Regimen to Longer Oral Regimen
- Refreshing BDQ course after switching between regimens
BPaLM: Supply chain Management of DR-TB drugs
BPaLM: Treatment outcome for DR-TB treatment
BPaLM: Reporting and Monitoring of DR-TB treatment
Cover
Updates in Management of DR-TB cases under NTEP